SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma

被引:17
作者
Hua, Hong-Wei [1 ,3 ]
Jiang, Hao-Sheng [3 ]
Jia, Ling [3 ]
Jia, Yi-Ping [3 ]
Yao, Yu-Lan [3 ]
Chen, Yi-Wen [3 ]
Jiang, Feng [2 ]
Lu, Dong-Qing [1 ]
Zhou, Qing [1 ]
Jiang, Ma-Wei [1 ]
Ding, Gang [3 ]
机构
[1] Shanghai Jiao Tong Univ, Oncol Dept, Xinhua Hosp, Sch Med, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Clin Res & Innovat Unit, Xinhua Hosp, Chongming Branch,Sch Med, Shanghai, Peoples R China
[3] Shanghai Int Med Ctr, Oncol Dept, Shanghai 200120, Peoples R China
关键词
Hepatocellular carcinoma; sorafenib; SPARC; ferroptosis; RESISTANCE; METABOLISM; IRON;
D O I
10.3233/CBM-200101
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Secreted protein acidic and rich in cysteine (SPARC) is implicated in cancer progression, but its role and associated molecular mechanism in the sorafenib sensitivity of hepatocellular carcinoma cells (HCC) remains elusive. METHODS: Human HCC cell lines Hep3B and HepG2 were treated with sorafenib alone or combined with activator or inhibitor of ferroptosis. Cell viability assay, reactive oxygen species (ROS) assay, lactate dehydrogenase (LDH) assay and western blot were used to study the regulatory mechanism of SPARC on HCC cells. RESULTS: Overexpression of SPARC enhanced the cytotoxic effect of sorafenib in Hep3B and HepG2 cells compared with parental cells. Depletion of SPARC decreased the cytotoxic effect of sorafenib in Hep3B and HepG2 cells compared with parental cells. Moreover, overexpression of SPARC significantly induced LDH release, whereas depletion of SPARC suppressed the release of LDH in Hep3B and HepG2 cells. Inhibition of ferroptosis exerted a clear inhibitory role against LDH release, whereas activation of ferroptosis promoted the release of LDH in HCC cells, as accompanied with deregulated expression of ferroptosis-related proteins. Furthermore, overexpression of SPARC induced oxidative stress, whereas depletion of SPARC suppressed the production of ROS. Deferoxamine (DFX)-induced inhibition of ferroptosis suppressed the production of ROS, while activation of ferroptosis promoted the contents of ROS in HCC cells exposed to sorafenib. CONCLUSION: Our findings give a better understanding of ferroptosis and its molecular mechanism in HCC cells that is regulated by SPARC in response to sorafenib.
引用
收藏
页码:425 / 433
页数:9
相关论文
共 26 条
  • [11] Molecular therapies and precision medicine for hepatocellular carcinoma
    Llovet, Josep M.
    Montal, Robert
    Sia, Daniela
    Finn, Richard S.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (10) : 599 - 616
  • [12] The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells
    Louandre, Christophe
    Marcq, Ingrid
    Bouhlal, Hicham
    Lachaier, Emma
    Godin, Corinne
    Saidak, Zuzana
    Francois, Catherine
    Chatelain, Denis
    Debuysscher, Veronique
    Barbare, Jean-Claude
    Chauffert, Bruno
    Galmiche, Antoine
    [J]. CANCER LETTERS, 2015, 356 (02) : 971 - 977
  • [13] Low expression of SPARC in gastric cancer-associated fibroblasts leads to stemness transformation and 5-fluorouracil resistance in gastric cancer
    Ma, Yongchen
    Zhu, Jing
    Chen, Shanwen
    Ma, Ju
    Zhang, Xiaoqian
    Huang, Sixia
    Hu, Jianwen
    Yue, Taohua
    Zhang, Junling
    Wang, Pengyuan
    Wang, Xin
    Rong, Long
    Guo, Hongjie
    Chen, Guowei
    Liu, Yucun
    [J]. CANCER CELL INTERNATIONAL, 2019, 19
  • [14] Treatment of advanced hepatocellular carcinoma: beyond sorafenib
    Meyer, Tim
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (04) : 218 - 220
  • [15] Role of SPARC in Bone Remodeling and Cancer-Related Bone Metastasis
    Ribeiro, Nilza
    Sousa, Susana R.
    Brekken, Rolf A.
    Monteiro, Fernado J.
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2014, 115 (01) : 17 - 26
  • [16] The role of SPARC in the TRAMP model of prostate carcinogenesis and progression
    Said, N.
    Frierson, H. F., Jr.
    Chernauskas, D.
    Conaway, M.
    Motamed, K.
    Theodorescu, D.
    [J]. ONCOGENE, 2009, 28 (39) : 3487 - 3498
  • [17] Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
    Shen, Y-C
    Ou, D-L
    Hsu, C.
    Lin, K-L
    Chang, C-Y
    Lin, C-Y
    Liu, S-H
    Cheng, A-L
    [J]. BRITISH JOURNAL OF CANCER, 2013, 108 (01) : 72 - 81
  • [18] Emerging Strategies of Cancer Therapy Based on Ferroptosis
    Shen, Zheyu
    Song, Jibin
    Yung, Bryant C.
    Zhou, Zijian
    Wu, Aiguo
    Chen, Xiaoyuan
    [J]. ADVANCED MATERIALS, 2018, 30 (12)
  • [19] Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
    Stockwell, Brent R.
    Angeli, Jose Pedro Friedmann
    Bayir, Hulya
    Bush, Ashley I.
    Conrad, Marcus
    Dixon, Scott J.
    Fulda, Simone
    Gascon, Sergio
    Hatzios, Stavroula K.
    Kagan, Valerian E.
    Noel, Kay
    Jiang, Xuejun
    Linkermann, Andreas
    Murphy, Maureen E.
    Overholtzer, Michael
    Oyagi, Atsushi
    Pagnussat, Gabriela C.
    Park, Jason
    Ran, Qitao
    Rosenfeld, Craig S.
    Salnikow, Konstantin
    Tang, Daolin
    Torti, Frank M.
    Torti, Suzy V.
    Toyokuni, Shinya
    Woerpel, K. A.
    Zhang, Donna D.
    [J]. CELL, 2017, 171 (02) : 273 - 285
  • [20] Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy
    Tai, IT
    Dai, M
    Owen, DA
    Chen, LB
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (06) : 1492 - 1502